| Acquired immune deficiency syndrome in the heart of Africa. | B M Mayosi (Cape Town, ZA) | Epidemiology & prevention | 01 Sep 2009 |
| Hypertension: meeting the need in Africa. | D Lemogoum (Brussels, BE) | Epidemiology & prevention | 01 Sep 2009 |
| Advances in the medical and surgical treatment of endomyocardial fibrosis. | A O Mocumbi (Maputo, MZ) | Epidemiology & prevention | 01 Sep 2009 |
| The role of Pan African Society of Cardiology. | A G B Amoah (Accra., GH) | Epidemiology & prevention | 01 Sep 2009 |
| Hypertension and peripheral disease. | D L Clement (Gent, BE) | Hypertension | 01 Sep 2009 |
| Heart failure and hotlines. | G Filippatos (Athens, GR) | Heart failure / LV dysfunction | 01 Sep 2009 |
| Risk stratification and coronary heart disease. | S Silber (Muenchen, DE) | Epidemiology & prevention | 01 Sep 2009 |
| Stroke and imaging. | C Rapezzi (Bologna, IT) | Peripheral circulation/Stroke | 01 Sep 2009 |
| Arrhythmia and pacing. | J Brugada Terradellas (Barcelona, ES) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| Effects of Valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (KYOTO Heart Study). | H Matsubara (Kamigyo-ku, JP) | Hypertension | 01 Sep 2009 |
| KYOTO Heart Study: Discussant. | F Ruschitzka (Zurich, CH) | Hypertension | 01 Sep 2009 |
| Effects of Rolofylline in Patients with Acute Heart Failure Syndrome and Renal Impairment: Findings from the PROTECT- Study. | M Metra (Brescia, IT) | Heart failure / LV dysfunction | 01 Sep 2009 |
| PROTECT-Study: Discussant. | M Jessup (Philadelphia, US) | Heart failure / LV dysfunction | 01 Sep 2009 |
| A randomized evaluation of irbesartan versus placebo in patients with Atrial Fibrillation (factorial design of ACTIVE Program). | S Yusuf (Hamilton, CA) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| ACTIVE Program: Discussant. | J Brugada Terradellas (Barcelona, ES) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| European CRT Survey. | N Bogale (Stavanger, NO) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| European CRT Survery: Discussant. | J C Daubert (Rennes, FR) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| Prevention of Sudden Cardiac Death in Post Myocardial Infarction Patients: Risk Stratification, ICD Therapy Penetration and Related Longterm Outcome: Final Results of the German PreSCD II Registry. | H Voeller (Rudersdorf, DE) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| German PreSCD II Registry: Discussant. | P E Vardas (Heraklion, GR) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| Multimodality imaging in coronary heart disease. | H J Ukkonen (Turku, FI) | Nuclear cardiology, CMR & CT | 01 Sep 2009 |
| Endocarditis is a changing disease: an epidemiological point of view. | B Hoen (Besancon, FR) | Valvular disease | 01 Sep 2009 |
| Prevention or prophylaxis? Is antibiotic prophylaxis still necessary? | P Moreillon (Lausanne, CH) | Valvular disease | 01 Sep 2009 |
| Prognostic assessment. | I Vilacosta (Madrid, ES) | Valvular disease | 01 Sep 2009 |
| Indications and optimal timing for surgery. | P Tornos Mas (Barcelona, ES) | Valvular disease | 01 Sep 2009 |
| ESC/ERS pulmonary hypertension Guidelines: Classification. | G Simonneau (Clamart Cedex, FR) | Pulmonary circulation | 01 Sep 2009 |
| ESC/ERS pulmonary hypertension Guidelines: Diagnosis. | A Torbicki (Warsaw, PL) | Pulmonary circulation | 01 Sep 2009 |
| ESC/ERS pulmonary hypertension Guidelines: Risk stratification and follow-up. | M M Hoeper (Hannover, DE) | Pulmonary circulation | 01 Sep 2009 |
| ESC/ERS pulmonary hypertension Guidelines: Treatment. | J S Russell Gibbs (London, GB) | Pulmonary circulation | 01 Sep 2009 |
| Predicting cardiovascular disease: does C-reactive protein add anything? | T A Pearson (Rochester, US) | Epidemiology & prevention | 01 Sep 2009 |
| Stroke prevention in atrial fibrillation: who should be on more than aspirin? | J W Mant (Cambridge, GB) | Arrhythmias / Pacing / Resynchronisation | 01 Sep 2009 |
| What's the quality of cardiovascular care in European primary care? | S Ludt (Heidelberg, DE) | Epidemiology & prevention | 01 Sep 2009 |
| Differences in heart failure management: the dimension of the problem. | P Ponikowski (Wroclaw, PL) | Heart failure / LV dysfunction | 01 Sep 2009 |
| The challenges in Europe. | A P Maggioni (Florence, IT) | Heart failure / LV dysfunction | 01 Sep 2009 |
| The challenges in the United States. | C O'Connor (Durham, US) | Heart failure / LV dysfunction | 01 Sep 2009 |
| Moving forward to global strategies. | M Gheorghiade (Chicago, US) | Heart failure / LV dysfunction | 01 Sep 2009 |
| Cardiotoxicity of old anticancer agents. | F Quaini (Parma, IT) | Pharmacology and pharmacotherapy | 01 Sep 2009 |
| Cardiotoxicity of new anticancer agents. | J Baselga (Barcelona, ES) | Pharmacology and pharmacotherapy | 01 Sep 2009 |
| Imaging: the cardiotoxicity of anticancer agents. | D Mele (Ferrara, IT) | Pharmacology and pharmacotherapy | 01 Sep 2009 |
| How to prevent the cardiotoxicity of anticancer agents. | T M Suter (Bern, CH) | Pharmacology and pharmacotherapy | 01 Sep 2009 |
| Imaging in asymptomatic subject: what in whom? | M Al-Mallah (Detroit, US) | Nuclear cardiology, CMR & CT | 01 Sep 2009 |
| Matching techniques to clinical needs: which test for which question? | J J Bax (Leiden, NL) | Nuclear cardiology, CMR & CT | 01 Sep 2009 |
| Is imaging adding incremental prognostic power to biomarkers? | R Gibbons (Rochester, US) | Nuclear cardiology, CMR & CT | 01 Sep 2009 |
| New clinical perspectives from imaging technologies. | J M Knuuti (Turku, FI) | Nuclear cardiology, CMR & CT | 01 Sep 2009 |
| Exercise and mitochondrial biogenesis. | R Ventura-Clapier (Chatenay-Malabry, FR) | Epidemiology & prevention | 01 Sep 2009 |
| Differential impact of training regime on cardiac muscle biology. | O J Kemi (Glasgow, GB) | Epidemiology & prevention | 01 Sep 2009 |
| Improving outcomes with exercise: fitness or risk factors? | L E M Vanhees (Leuven, BE) | Epidemiology & prevention | 01 Sep 2009 |
| Optimising exercise training for global cardiovascular health. | R Hambrecht (Bremen, DE) | Epidemiology & prevention | 01 Sep 2009 |
| Mechanisms of arterial ageing. | J R Cockcroft (Cardiff, GB) | Epidemiology & prevention | 01 Sep 2009 |
| Morphological and functional changes of the aged arteries. | J Lekakis (Haidari, Athens, GR) | Epidemiology & prevention | 01 Sep 2009 |
| Differences between arterial ageing and atherosclerosis. | L Tokgozoglu (Ankara, TR) | Epidemiology & prevention | 01 Sep 2009 |
| Renin and the prorenin/renin receptor. | T Unger (Berlin, DE) | Hypertension | 01 Sep 2009 |
| Antifibrotic and destiffening drugs. | W J Paulus (Amsterdam, NL) | Hypertension | 01 Sep 2009 |
| Renalase. | E Ritz (Heidelberg, DE) | Hypertension | 01 Sep 2009 |
| Implantable devices for hypertension. | W T Abraham (Columbus, US) | Hypertension | 01 Sep 2009 |
| Subendothelial lipoprotein retention - a novel target to prevent atherosclerosis. | J Boren (Goteborg, SE) | Vascular biology | 01 Sep 2009 |
| Genetic determinants of statin response: what really matters? | R E Collins (Oxford, GB) | Vascular biology | 01 Sep 2009 |
| Should we be targeting triglycerides? | B G Nordestgaard (Copenhagen, DK) | Vascular biology | 01 Sep 2009 |
| Sphingosin-1-phosphate and vascular tone. | B Levkau (Essen, DE) | Vascular biology | 01 Sep 2009 |
| Reduction in the risk of heart failure with preventive cardiac resynchronization therapy: MADIT-CRT Trial. | A J Moss (Rochester, US) | Heart failure / LV dysfunction | 01 Sep 2009 |